Completed PHASE2 INTERVENTIONAL NCT00083707

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

UARK 99-006, A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Sponsor: Celgene Corporation

Conditions Waldenstrom Macroglobulinemia

Interventions Thalidomide

Updated 5 times since 2017 Last updated: Jul 1, 2010 Started: Jan 31, 1999 Completion: Feb 28, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Waldenstrom Macroglobulinemia, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 5 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
University of Arkansas

Data source: University of Arkansas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Little Rock, United States